Aardvark Therapeutics Inc
AARD
Company Profile
Business description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Contact
4370 La Jolla Village Drive
Suite 1050
San DiegoCA92122
USAT: +1 858 225-7696
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
28
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 6.40 | 0.07% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,622.78 | 136.29 | 0.26% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,474.23 | 8.04 | 0.03% |
| Nikkei 225 | 60,819.36 | 359.78 | 0.60% |
| NZX 50 Index | 14,259.23 | 91.82 | 0.65% |
| S&P 500 | 7,629.21 | 9.83 | 0.13% |
| S&P/ASX 200 | 9,146.80 | 17.80 | 0.19% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |